Literature DB >> 11432120

Treatment of Alzheimer's disease.

J L Cummings1.   

Abstract

A growing consensus indicates that Alzheimer's disease (AD) results from an increase in the production or accumulation of beta-amyloid protein (A beta) leading to nerve cell death. Mechanisms by which A beta accumulation leads to neuronal death include oxidative damage and inflammation. This article discusses the management of AD patients with antioxidants, cholinesterase inhibitors, and psychotropic agents. Studies show that these agents can slow the progression of the disease, improve cognition, and reduce behavioral disturbances. A therapeutic alliance between physician and caregiver is an essential element in successfully managing the AD patient. The 3Rs--repeat, reassure, and redirect--can help caregivers reduce behavioral disturbances in patients with AD and limit the need for pharmacologic management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432120     DOI: 10.1016/s1098-3597(01)90046-8

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  4 in total

1.  Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.

Authors:  Alfred N Fonteh; Jiarong Chiang; Matthew Cipolla; Jack Hale; Fatimatou Diallo; Alejandra Chirino; Xianghong Arakaki; Michael G Harrington
Journal:  J Lipid Res       Date:  2013-07-18       Impact factor: 5.922

2.  Physiologic modulation of natural killer cell activity as an index of Alzheimer's disease progression.

Authors:  Paolo Prolo; Francesco Chiappelli; Alberto Angeli; Andrea Dovio; Paola Perotti; Marisa Pautasso; Maria Luisa Sartori; Laura Saba; Stefano Mussino; Thomas Fraccalini; Fausto Fantó; Cristina Mocellini; Maria Gabriella Rosso; Enzo Grasso
Journal:  Bioinformation       Date:  2007-03-21

3.  Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease.

Authors:  Francesco Chiappelli; Audrey M Navarro; David R Moradi; Ercolano Manfrini; Paolo Prolo
Journal:  Evid Based Complement Alternat Med       Date:  2006-11-10       Impact factor: 2.629

4.  Neuroendocrine immunity in patients with Alzheimer's disease: toward translational epigenetics.

Authors:  Francesco Chiappelli; Paolo Prolo; Kristine D Cajulis; Alberto Angeli; Andrea Dovio; Paola Perotti; Marisa Pautasso; Maria Luisa Sartori; Laura Saba; Stefano Mussino; Thomas Fraccalini; Fausto Fanto; Ercolano Manfrini; Cristina Mocellini; Maria Gabriella Rosso; Enzo Grasso
Journal:  Bioinformation       Date:  2007-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.